scholarly journals Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

2016 ◽  
Vol 16 (1) ◽  
pp. 43-52 ◽  
Author(s):  
Anthony Mills ◽  
Jose R Arribas ◽  
Jaime Andrade-Villanueva ◽  
Giovanni DiPerri ◽  
Jan Van Lunzen ◽  
...  
Author(s):  
Priya Kathuria

A clinical decision report using: Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23-e34. https://doi.org/10.1016/S2352-3018(17)30179-0 for a patient with viriologically suppressed HIV-1.


2020 ◽  
Vol 7 (10) ◽  
pp. e677-e687 ◽  
Author(s):  
Alexandra Calmy ◽  
Tamara Tovar Sanchez ◽  
Charles Kouanfack ◽  
Mireille Mpoudi-Etame ◽  
Sandrine Leroy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document